Pacific Biosciences of California(US:PACB) ZACKS·2026-02-12 23:35分组1 - Pacific Biosciences reported a quarterly loss of $0.12 per share, better than the Zacks Consensus Estimate of a loss of $0.19, representing an earnings surprise of +36.84% [1] - The company posted revenues of $44.65 million for the quarter ended December 2025, exceeding the Zacks Consensus Estimate by 9.42%, compared to $39.22 million in the same quarter last year [2] - The stock has underperformed the market, losing about 1.6% since the beginning of the year, while the S&P 500 gained 1.4% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is -$0.17 on revenues of $42 million, and for the current fiscal year, it is -$0.57 on revenues of $177.35 million [7] - The Zacks Industry Rank for Medical - Instruments is in the top 34% of over 250 Zacks industries, indicating a favorable outlook for the industry [8]